Located in the former Gainey Center, the new facility is a licensed, 61-bed residential addiction treatment and recovery center for alcohol- and drug-dependent adults and those with co-occurring mental health and substance abuse related issues.
According to a company statement, upon intake, patients will receive medical and chemical assessments, including Millennium Pharmacogenetic Testing—a non-invasive genetic test to help identify how the patient’s genetic profile may impact medication response and allow clinicians to make more effective personalized prescribing decisions.
Beauterre also will provide each patient with neuropsychiatric assessments as well as health and wellness assessments that allow for integrating a variety of therapies like biofeedback, acupuncture, massage and equine therapy into individual care plans.
“Our programs are based on the needs of the individual, specifically addressing the co-occurring mental health issues often intertwined with chemical dependency,” Sheila Specker, MD, medical director of Beauterre said in a statement.
Variable lengths of stay will also be offered based on an individual’s needs, including shorter stays for those who have successfully completed a treatment program in the past but have relapsed during recovery.
Get the latest information on Business Strategy and other valuable topics at this three-day retreat bringing together treatment center owners and executives and key members of the financial community for prime networking opportunities and in-depth discussions for those looking to grow, invest and transform their business.